California-based biotech innovator Abram Scientific is positioning itself at the vanguard of emergency trauma care, leveraging significant new federal funding to fast-track its CoagCare platform toward FDA clearance and military deployment.
In a major boost for point-of-care (POC) medical technology, Abram Scientific has been awarded a contract worth up to $8.3 million from the Defense Advanced Research Projects Agency (DARPA). This infusion of capital, aimed at advancing the company’s proprietary blood coagulation diagnostic platform, CoagCare, marks a pivotal moment for the firm as it pivots from late-stage development to potential regulatory filing and commercialization.
The contract arrives on the heels of a highly successful $10.75 million Series A financing round concluded in February 2026. Together, these financial milestones provide Abram with the necessary runway to bridge the gap between laboratory innovation and real-world application in both civilian and battlefield environments.
The Core Innovation: Redefining Hemostasis Monitoring
At the heart of the company’s mission is the CoagCare diagnostic system. Traditional methods for assessing blood coagulation, such as thromboelastography, are often restricted to centralized hospital laboratories and can require between 30 and 60 minutes to provide actionable data. In the context of severe trauma—where hemorrhage is a leading cause of preventable death—this delay can be catastrophic.
Abram’s CoagCare platform is engineered to shatter these temporal barriers. By assessing and characterizing a patient’s blood coagulation status in under 10 minutes, the device provides clinicians and first responders with the granular data required to make rapid, life-saving decisions regarding blood product administration and surgical intervention.
The technology is uniquely designed for portability, allowing "laboratory-quality" diagnostics to be moved from the controlled environment of a hospital to the challenging conditions of the field. This capability is precisely what attracted the attention of DARPA, an agency tasked with pioneering breakthrough technologies for U.S. national security.
Chronology of Development: A Steady Trajectory
Abram Scientific’s progress over the last eighteen months demonstrates a methodical approach to clinical and commercial validation:
- October 2025: Abram Scientific secures an initial $2 million tranche from DARPA. This seed funding was earmarked specifically for the miniaturization of the CoagCare system, ensuring the device could be ruggedized for military use.
- February 2026: The company successfully closes a $10.75 million Series A financing round. This influx of private capital signaled strong investor confidence in the platform’s clinical potential and regulatory roadmap.
- October 2026: The announcement of the $8.3 million DARPA contract. This represents a significant expansion of the partnership, shifting focus from pure R&D to manufacturing scaling, military-specific design iterations, and preparations for an FDA regulatory filing.
Supporting Data: The RAPIID Program and Technical Objectives
The $8.3 million award was granted under the DARPA Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. This program focuses on developing advanced medical interventions for casualties in resource-limited environments, where evacuation times are long and medical supplies are scarce.
The scope of the contract is multifaceted:
- FDA Regulatory Pathway: The funding is intended to provide the final push required to compile and submit the necessary clinical data for FDA clearance.
- Blood Analogue Optimization: A critical component of the contract involves optimizing CoagCare to support the administration of shelf-stable blood analogue components. In battlefield scenarios, the lack of fresh, refrigerated blood is a major constraint; the ability to test the efficacy of substitutes in real-time is a force multiplier for military medicine.
- Manufacturing Infrastructure: The funds will support the establishment of dedicated manufacturing capabilities for both the CoagCare meter and the disposable test cards, ensuring the supply chain is robust enough to handle potential defense-sector volume.
- System Design: Engineers will further refine the platform’s ergonomics, specifically tailoring the system design for military-focused portability without sacrificing the precision of the diagnostic output.
While the exact terms of the contract—including the milestones required to unlock the full $8.3 million—remain subject to internal review, the award confirms DARPA’s intent to integrate Abram’s technology into the future of trauma care.
Official Perspectives: Closing the Gap in Trauma Care
The leadership at Abram Scientific views this contract as a validation of their core philosophy: that diagnostic precision should not be tethered to the hospital wall.
Abhishek Ramkumar, founder and CEO of Abram Scientific, emphasized the human stakes of the company’s work. "Rapid access to actionable coagulation information can be critical for saving lives in trauma care, when every minute matters," Ramkumar stated. "This DARPA award recognizes the importance of bringing laboratory-quality coagulation information closer to the patient and supports our efforts to develop a platform that can ultimately serve both military and civilian medicine."
By bridging the gap between high-tech laboratory analysis and point-of-care accessibility, Abram aims to create a "universal" diagnostic standard. Whether in a rural ambulance, a disaster relief site, or an active conflict zone, the objective is to provide a "go-to" solution for clinicians managing complex coagulopathies.
Implications: The Future of Battlefield and Civilian Medicine
The integration of CoagCare into military medicine could fundamentally alter how trauma is managed in the "golden hour" following an injury. If successful, the platform will enable medics to assess whether a patient requires specific clotting factors or synthetic blood substitutes, preventing the dangerous "coagulopathy of trauma" that often leads to exsanguination.
Potential Clinical Impact
- Precision Medicine: Moving away from "one-size-fits-all" transfusion protocols to targeted, patient-specific interventions.
- Logistical Efficiency: By identifying exactly which blood components a patient needs, military medical units can better manage their limited inventory of blood products.
- Reduced Mortality: Shortening the diagnostic cycle from 60 minutes to 10 minutes provides a massive tactical advantage in survival outcomes.
Broader Market Implications
For the medical device industry, Abram’s success highlights a growing trend of "dual-use" technologies. Innovations initially designed for the rigors of the battlefield are increasingly being identified as the next generation of civilian medical equipment. As the company moves toward an FDA filing, the data generated will likely be closely watched by healthcare systems worldwide, particularly those in remote or underserved areas where access to centralized lab testing is unreliable.
The Road Ahead
While the path to commercialization is rarely without hurdles, Abram Scientific enters the final stages of its development cycle in a robust position. The company has successfully navigated the "Valley of Death"—the period in which startups often fail due to a lack of capital or clear clinical demand. With the dual backing of private equity and one of the world’s most sophisticated research agencies, the company is now tasked with executing a complex regulatory and manufacturing strategy.
If Abram can successfully translate its miniaturized, high-speed coagulation technology into a cleared, scalable medical product, it will represent a milestone in emergency medicine. The ability to characterize blood status on the front lines, or at the scene of a highway accident, could redefine the standard of care for hemorrhage patients globally, effectively turning the battlefield into a high-functioning diagnostic hub.
As the company prepares for its upcoming FDA submission, the eyes of the trauma care community remain fixed on this California innovator. For Abram Scientific, the mission is clear: to ensure that when every second counts, the technology is already waiting, ready to deliver the answers needed to save a life.
About the Author
